Archives
-
Gut Dysbiosis, STAT3, and Docetaxel Resistance
2026-09-30
Zhong et al. identify a microbiome–tumor communication route in which antibiotic-associated dysbiosis increases intestinal permeability and intratumoral lipopolysaccharide, activating the NF-κB–IL6–STAT3 axis in prostate cancer. The study combines mouse models, fecal microbiota transplantation, 16S rRNA profiling, mechanistic assays, and patient data to connect microbial composition with tumor progression and docetaxel resistance.
-
EGFP mRNA Workflows for RNA Delivery
2026-09-30
Use EGFP mRNA as a practical fluorescent benchmark for comparing RNA delivery, cell entry, and protein-expression workflows. This guide connects a capped, modified reporter transcript with the emerging potato virus X nucleoprotein platform while separating evidence-backed findings from recommended assay starting points.
-
Anti-DLL3 Antibody: SCLC Research Workflows
2026-09-29
Build a DLL3 research workflow that moves from protein detection and cell-surface profiling to functional and preclinical studies. The Dragonfly patent anti-DLL3 format adds an unconjugated, flexible reagent for evaluating target biology alongside emerging transient DLL3-directed CAR-T strategies.
-
Lypressin Acetate: From Receptor Biology to Translation
2026-09-29
A translational framework for using Lypressin acetate to connect vasopressin receptor pharmacology, endocrine research, vasopressor assays, and carefully bounded antiviral hypotheses.
-
Prostaglandin E2 Workflows for Immune Research
2026-09-28
Use Prostaglandin E2 as a controlled GPCR perturbation tool for inflammation research, immune regulation, barrier models, and receptor-resolved assay design. This guide translates new arachidonic-acid immunity findings into practical PGE2 comparator experiments while separating established evidence from testable hypotheses.
-
Stattic Workflows for STAT3-Driven Research
2026-09-28
Use Stattic to test whether STAT3 signaling contributes to cancer-cell survival, migration, or treatment response—not simply to label a phenotype as STAT3-dependent. This practical guide connects HNSCC assay design with a recent endothelial-cell study, while distinguishing published findings from suggested optimization conditions.
-
Bufuralol (hydrochloride) for Reliable Assays
2026-09-27
Learn how to use Bufuralol (hydrochloride), SKU C5043, thoughtfully in β-adrenergic research and cell-based workflows without confusing pharmacological effects with cytotoxicity. This scenario-led guide covers assay controls, solvent compatibility, organoid-model limitations, and practical reagent selection, with links to product information and relevant literature.
-
Procainamide Hydrochloride: Assay Workflows
2026-09-26
Build distinct, control-rich workflows for Nav1.5 electrophysiology, myeloid-cell assays, and DNMT1-related studies with Procainamide Hydrochloride. A macrophage phenotypic-screening study offers useful assay-design ideas—but does not establish procainamide as an SPP1-targeting compound.
-
Tankyrase Inhibition Restrains HCC Through Hippo Signaling
2026-09-25
Jia and colleagues found that the tankyrase inhibitors G007-LK and XAV-939 suppress colony formation in human hepatocellular carcinoma cell lines while reducing YAP activity and increasing AMOTL1 and AMOTL2 protein levels. The study connects tankyrase inhibition to Hippo-pathway regulation and suggests a rationale for testing tankyrase inhibitors alongside MEK or AKT inhibitors, while leaving efficacy in animal models and patients unresolved.
-
G007-LK Tankyrase 1/2 Inhibitor: Evidence
2026-09-25
G007-LK is a potent tankyrase 1/2 inhibitor used to investigate Wnt/β-catenin signaling pathway inhibition and related cancer biology. Product data and preclinical studies report effects on tankyrase activity, β-catenin regulation, and tumor-cell growth, but these findings do not establish clinical efficacy.
-
Measuring Drug Response: Growth Arrest vs Cell Death
2026-09-24
Hannah R. Schwartz’s dissertation highlights why relative viability and fractional viability should not be treated as interchangeable measures of anticancer drug response. Its central implication is practical: separating growth inhibition from cell killing, and tracking when each occurs, can make in vitro results easier to interpret and compare.
-
From RHEB Mechanism to Translational Protein Workflows
2026-09-24
A study of UBE2F–SAG-driven RHEB neddylation offers a mechanistic entry point for translational liver-cancer research—and a reminder that protein purification choices must be designed around the question being asked. This article connects the findings to practical validation strategies using X-press Tag Peptide while distinguishing biochemical support from cellular and clinical evidence.
-
Disulfiram in Cell Assays: Practical Design Guide
2026-09-23
A scenario-based guide to planning Disulfiram experiments for cell viability, apoptosis, and proteasome studies. It connects the ALDH2 findings in APC-deficient colorectal cancer with product-specific handling details for Disulfiram SKU A4015, while distinguishing supported evidence from workflow recommendations.
-
Mifepristone (RU486): A Multimodal Assay Playbook
2026-09-23
Mifepristone (RU486) is more than a progesterone receptor antagonist: it is a useful probe for connecting receptor biology, cell-state transitions, and functional phenotypes. This guide translates an integrated transcriptomic–phenotypic screening framework into practical assay decisions for oncology, reproductive biology, and safety research.
-
Targeted EPO mRNA Nanoparticles for Spinal Cord Repair
2026-09-22
This study developed mannose-modified lipid nanoparticles that deliver human erythropoietin mRNA to CD206-enriched inflammatory macrophages and microglia after spinal cord injury. In mice, localized EPO production was associated with reduced neuroinflammation, suppression of ferroptosis-related damage, preservation of serotonergic axons, and improved motor recovery.